Neoadjuvant therapy for non-small cell lung cancer

Anti-Cancer Drugs

Volumn 12, Issue SUPPL. 1, 2001, Pages

  Gandara, D R ^a   Lara P N , Jr ^a   Goldberg, Z ^a   Roberts, P ^a   Lau, D H M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Neoadjuvant therapy; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOSENSITIVITY; CONFERENCE PAPER; HUMAN; LUNG NON SMALL CELL CANCER; PREOPERATIVE TREATMENT; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOADJUVANT THERAPY; NEOPLASM STAGING; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS; TAXOIDS;

EID: 0035056903     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (21)

1. Cancer statistics, 1999
2. Revisions in the international systems for staging lung cancer
3. Multi-modality therapy in stage III non-small cell lung cancer
4. Commentary on multimodality therapy for non-small cell lung cancer
5. Novel therapeutic approaches in advanced non-small cell lung cancer
6. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials
7. What does chemotherapy have to offer patients with advanced non-small cell lung cancer?
8. Induction chemotherapy before surgery for early-stage lung cancer: A novel approach
9. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer
10. A randomized trial comparing pre-operative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer
11. Role of multimodality treatment for lung cancer
12. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small cell lung cancer: Mature results of SWOG 8805
13. Long term survival after concurrent cisplatin/etoposide (PE) plus chest radiotherapy (RT) followed by surgery in bulky, stages IIIa (N2) and IIIB non-small cell lung cancer (NSCLC): 6 year outcomes from Southwest Oncology Group Lung Committee 8805
14. 0) non-small cell lung cancer (NSCLC)
15. A prospective randomized trial of docetaxel (Taxotere®) versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy
16. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens
17. Docetaxel enhances tumor radioresponse in vivo
18. Outpatient Taxotere/carboplatin combination therapy in NSCLC for induction in Stage IIIB and palliation in state IV
19. 2 is highly active with few toxicities
20. New approaches in the adjuvant and neoadjuvant therapy of non-small cell lung cancer, including docetaxel (Taxotere) combinations
21. Taxotere as neoadjuvant therapy for radically treatable stage III NSCLC. Preliminary results of an international phase III study